 | • レポートコード：MRC23Q36215 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の非侵襲的リキッドバイオプシー市場について調査・分析し、世界の非侵襲的リキッドバイオプシー市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（便検査、尿検査、唾液検査、その他）、用途別セグメント分析（病院、研究所、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bio-Techne、Endress+Hauser、Exact Sciences Corporation、Lonza Group AG、MDxHealth、Merck KGaA、MutantDx、Norgen Biotek Corp、Nucleix、Oasis Diagnostics Corporation、OraSure Technologies、PerkinElmer、Predicine、Qiagen、Thermo Fisher Scientific、Zymo Research Corporationなどが含まれています。世界の非侵襲的リキッドバイオプシー市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、非侵襲的リキッドバイオプシー市場規模を推定する際に考慮しました。本レポートは、非侵襲的リキッドバイオプシーの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、非侵襲的リキッドバイオプシーに関するビジネス上の意思決定に役立てることを目的としています。 ・非侵襲的リキッドバイオプシー市場の概要 - 非侵襲的リキッドバイオプシーのタイプ別セグメント - 世界の非侵襲的リキッドバイオプシー市場規模：タイプ別分析（便検査、尿検査、唾液検査、その他） - 非侵襲的リキッドバイオプシーの用途別セグメント - 世界の非侵襲的リキッドバイオプシー市場規模：用途別分析（病院、研究所、その他） - 世界の非侵襲的リキッドバイオプシー市場規模予測（2018年-2029年） ・非侵襲的リキッドバイオプシー市場の成長トレンド - 非侵襲的リキッドバイオプシーの地域別市場規模（2018年-2029年） - 非侵襲的リキッドバイオプシー市場ダイナミクス - 非侵襲的リキッドバイオプシーの業界動向 - 非侵襲的リキッドバイオプシー市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：便検査、尿検査、唾液検査、その他 - 世界の非侵襲的リキッドバイオプシーのタイプ別市場規模（2018年-2023年） - 世界の非侵襲的リキッドバイオプシーのタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、研究所、その他 - 世界の非侵襲的リキッドバイオプシーの用途別市場規模（2018年-2023年） - 世界の非侵襲的リキッドバイオプシーの用途別市場規模（2024年-2029年） ・非侵襲的リキッドバイオプシーの地域別市場規模 - 北米の非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - アメリカの非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - ヨーロッパの非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - アジア太平洋の非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - 中国の非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - 日本の非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - 韓国の非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - インドの非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - オーストラリアの非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - 中南米の非侵襲的リキッドバイオプシー市場規模（2018年-2029年） - 中東・アフリカの非侵襲的リキッドバイオプシー市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Bio-Techne、Endress+Hauser、Exact Sciences Corporation、Lonza Group AG、MDxHealth、Merck KGaA、MutantDx、Norgen Biotek Corp、Nucleix、Oasis Diagnostics Corporation、OraSure Technologies、PerkinElmer、Predicine、Qiagen、Thermo Fisher Scientific、Zymo Research Corporation ・アナリストの観点/結論 ・調査方法とデータソース |
Non-invasive liquid biopsy is to analyze and diagnose diseases such as cancer through blood or urine and other body fluids. At present, the main application area of liquid biopsy is the blood detection of tumors, that is, the use of blood to indicate tumor development and drug resistance and other information to guide individualized and precise treatment. Compared with existing tumor detection methods, liquid biopsy is non-invasive, can be detected frequently and repeatedly, and has rapid response capabilities. It has significant advantages and has great potential for application development.
Highlights
The global Non-Invasive Liquid Biopsy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Non-Invasive Liquid Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Non-Invasive Liquid Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Non-Invasive Liquid Biopsy in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Non-Invasive Liquid Biopsy include Bio-Techne, Endress+Hauser, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp and Nucleix, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Non-Invasive Liquid Biopsy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Invasive Liquid Biopsy.
The Non-Invasive Liquid Biopsy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Non-Invasive Liquid Biopsy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Invasive Liquid Biopsy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bio-Techne
Endress+Hauser
Exact Sciences Corporation
Lonza Group AG
MDxHealth
Merck KGaA
MutantDx
Norgen Biotek Corp
Nucleix
Oasis Diagnostics Corporation
OraSure Technologies
PerkinElmer
Predicine
Qiagen
Thermo Fisher Scientific
Zymo Research Corporation
Segment by Type
Stool Test
Urine Test
Saliva Test
Others
Segment by Application
Hospital
Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Invasive Liquid Biopsy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Invasive Liquid Biopsy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Stool Test
1.2.3 Urine Test
1.2.4 Saliva Test
1.2.5 Others
1.3 Market by Application
1.3.1 Global Non-Invasive Liquid Biopsy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Laboratory
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Invasive Liquid Biopsy Market Perspective (2018-2029)
2.2 Non-Invasive Liquid Biopsy Growth Trends by Region
2.2.1 Global Non-Invasive Liquid Biopsy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-Invasive Liquid Biopsy Historic Market Size by Region (2018-2023)
2.2.3 Non-Invasive Liquid Biopsy Forecasted Market Size by Region (2024-2029)
2.3 Non-Invasive Liquid Biopsy Market Dynamics
2.3.1 Non-Invasive Liquid Biopsy Industry Trends
2.3.2 Non-Invasive Liquid Biopsy Market Drivers
2.3.3 Non-Invasive Liquid Biopsy Market Challenges
2.3.4 Non-Invasive Liquid Biopsy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Invasive Liquid Biopsy Players by Revenue
3.1.1 Global Top Non-Invasive Liquid Biopsy Players by Revenue (2018-2023)
3.1.2 Global Non-Invasive Liquid Biopsy Revenue Market Share by Players (2018-2023)
3.2 Global Non-Invasive Liquid Biopsy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Invasive Liquid Biopsy Revenue
3.4 Global Non-Invasive Liquid Biopsy Market Concentration Ratio
3.4.1 Global Non-Invasive Liquid Biopsy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Invasive Liquid Biopsy Revenue in 2022
3.5 Non-Invasive Liquid Biopsy Key Players Head office and Area Served
3.6 Key Players Non-Invasive Liquid Biopsy Product Solution and Service
3.7 Date of Enter into Non-Invasive Liquid Biopsy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Invasive Liquid Biopsy Breakdown Data by Type
4.1 Global Non-Invasive Liquid Biopsy Historic Market Size by Type (2018-2023)
4.2 Global Non-Invasive Liquid Biopsy Forecasted Market Size by Type (2024-2029)
5 Non-Invasive Liquid Biopsy Breakdown Data by Application
5.1 Global Non-Invasive Liquid Biopsy Historic Market Size by Application (2018-2023)
5.2 Global Non-Invasive Liquid Biopsy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Non-Invasive Liquid Biopsy Market Size (2018-2029)
6.2 North America Non-Invasive Liquid Biopsy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Non-Invasive Liquid Biopsy Market Size by Country (2018-2023)
6.4 North America Non-Invasive Liquid Biopsy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Invasive Liquid Biopsy Market Size (2018-2029)
7.2 Europe Non-Invasive Liquid Biopsy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Non-Invasive Liquid Biopsy Market Size by Country (2018-2023)
7.4 Europe Non-Invasive Liquid Biopsy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Invasive Liquid Biopsy Market Size (2018-2029)
8.2 Asia-Pacific Non-Invasive Liquid Biopsy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Non-Invasive Liquid Biopsy Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-Invasive Liquid Biopsy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Invasive Liquid Biopsy Market Size (2018-2029)
9.2 Latin America Non-Invasive Liquid Biopsy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Non-Invasive Liquid Biopsy Market Size by Country (2018-2023)
9.4 Latin America Non-Invasive Liquid Biopsy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Invasive Liquid Biopsy Market Size (2018-2029)
10.2 Middle East & Africa Non-Invasive Liquid Biopsy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Non-Invasive Liquid Biopsy Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-Invasive Liquid Biopsy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bio-Techne
11.1.1 Bio-Techne Company Detail
11.1.2 Bio-Techne Business Overview
11.1.3 Bio-Techne Non-Invasive Liquid Biopsy Introduction
11.1.4 Bio-Techne Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.1.5 Bio-Techne Recent Development
11.2 Endress+Hauser
11.2.1 Endress+Hauser Company Detail
11.2.2 Endress+Hauser Business Overview
11.2.3 Endress+Hauser Non-Invasive Liquid Biopsy Introduction
11.2.4 Endress+Hauser Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.2.5 Endress+Hauser Recent Development
11.3 Exact Sciences Corporation
11.3.1 Exact Sciences Corporation Company Detail
11.3.2 Exact Sciences Corporation Business Overview
11.3.3 Exact Sciences Corporation Non-Invasive Liquid Biopsy Introduction
11.3.4 Exact Sciences Corporation Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.3.5 Exact Sciences Corporation Recent Development
11.4 Lonza Group AG
11.4.1 Lonza Group AG Company Detail
11.4.2 Lonza Group AG Business Overview
11.4.3 Lonza Group AG Non-Invasive Liquid Biopsy Introduction
11.4.4 Lonza Group AG Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.4.5 Lonza Group AG Recent Development
11.5 MDxHealth
11.5.1 MDxHealth Company Detail
11.5.2 MDxHealth Business Overview
11.5.3 MDxHealth Non-Invasive Liquid Biopsy Introduction
11.5.4 MDxHealth Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.5.5 MDxHealth Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Detail
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Non-Invasive Liquid Biopsy Introduction
11.6.4 Merck KGaA Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.6.5 Merck KGaA Recent Development
11.7 MutantDx
11.7.1 MutantDx Company Detail
11.7.2 MutantDx Business Overview
11.7.3 MutantDx Non-Invasive Liquid Biopsy Introduction
11.7.4 MutantDx Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.7.5 MutantDx Recent Development
11.8 Norgen Biotek Corp
11.8.1 Norgen Biotek Corp Company Detail
11.8.2 Norgen Biotek Corp Business Overview
11.8.3 Norgen Biotek Corp Non-Invasive Liquid Biopsy Introduction
11.8.4 Norgen Biotek Corp Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.8.5 Norgen Biotek Corp Recent Development
11.9 Nucleix
11.9.1 Nucleix Company Detail
11.9.2 Nucleix Business Overview
11.9.3 Nucleix Non-Invasive Liquid Biopsy Introduction
11.9.4 Nucleix Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.9.5 Nucleix Recent Development
11.10 Oasis Diagnostics Corporation
11.10.1 Oasis Diagnostics Corporation Company Detail
11.10.2 Oasis Diagnostics Corporation Business Overview
11.10.3 Oasis Diagnostics Corporation Non-Invasive Liquid Biopsy Introduction
11.10.4 Oasis Diagnostics Corporation Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.10.5 Oasis Diagnostics Corporation Recent Development
11.11 OraSure Technologies
11.11.1 OraSure Technologies Company Detail
11.11.2 OraSure Technologies Business Overview
11.11.3 OraSure Technologies Non-Invasive Liquid Biopsy Introduction
11.11.4 OraSure Technologies Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.11.5 OraSure Technologies Recent Development
11.12 PerkinElmer
11.12.1 PerkinElmer Company Detail
11.12.2 PerkinElmer Business Overview
11.12.3 PerkinElmer Non-Invasive Liquid Biopsy Introduction
11.12.4 PerkinElmer Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.12.5 PerkinElmer Recent Development
11.13 Predicine
11.13.1 Predicine Company Detail
11.13.2 Predicine Business Overview
11.13.3 Predicine Non-Invasive Liquid Biopsy Introduction
11.13.4 Predicine Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.13.5 Predicine Recent Development
11.14 Qiagen
11.14.1 Qiagen Company Detail
11.14.2 Qiagen Business Overview
11.14.3 Qiagen Non-Invasive Liquid Biopsy Introduction
11.14.4 Qiagen Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.14.5 Qiagen Recent Development
11.15 Thermo Fisher Scientific
11.15.1 Thermo Fisher Scientific Company Detail
11.15.2 Thermo Fisher Scientific Business Overview
11.15.3 Thermo Fisher Scientific Non-Invasive Liquid Biopsy Introduction
11.15.4 Thermo Fisher Scientific Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.15.5 Thermo Fisher Scientific Recent Development
11.16 Zymo Research Corporation
11.16.1 Zymo Research Corporation Company Detail
11.16.2 Zymo Research Corporation Business Overview
11.16.3 Zymo Research Corporation Non-Invasive Liquid Biopsy Introduction
11.16.4 Zymo Research Corporation Revenue in Non-Invasive Liquid Biopsy Business (2018-2023)
11.16.5 Zymo Research Corporation Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details